Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Jiangsu Hengrui Pharmaceuticals Co's share price is ¥54.91.
Jiangsu Hengrui Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥4.90. Hence, Jiangsu Hengrui Pharmaceuticals Co's PS Ratio for today is 11.21.
During the past 13 years, Jiangsu Hengrui Pharmaceuticals Co's highest 3-Year average Revenue per Share Growth Rate was 36.40% per year. The lowest was -6.00% per year. And the median was 20.60% per year.
Back to Basics: PS Ratio
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Jiangsu Hengrui Pharmaceuticals Co PS Ratio Related Terms
Jiangsu Hengrui Pharmaceuticals Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's PS Ratio falls into.
Jiangsu Hengrui Pharmaceuticals Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Jiangsu Hengrui Pharmaceuticals Co's Share Price of today is ¥54.91. Jiangsu Hengrui Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4.90.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a PS Ratio of 11.21 as of Jul. 23, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is 11% below median its historical median of 12.64. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's PS Ratio has ranged from 7.65 to 23.82. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #844 out of 952 companies in the Drug Manufacturers industry, placing it in the top 88.7%.
Is Jiangsu Hengrui Pharmaceuticals Co's PS Ratio too high?
Jiangsu Hengrui Pharmaceuticals Co's current PS Ratio of 11.21 is 11% below median its 10-year median of 12.64. Over the past 10 years, this metric has ranged from a low of 7.65 to a high of 23.82. The Drug Manufacturers industry median PS Ratio is 2.30. Jiangsu Hengrui Pharmaceuticals Co's value of 11.21 is 388.5% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #844 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #844 out of 952 companies for PS Ratio. This places Jiangsu Hengrui Pharmaceuticals Co in the lower half of its industry. The industry median PS Ratio is 2.30. Jiangsu Hengrui Pharmaceuticals Co's value of 11.21 is 388.5% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own PS Ratio has ranged from 7.65 to 23.82 over the past decade. While the company's 10-year median is 12.64 vs. the industry median of 2.30, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current PS Ratio of 11.21 is 388.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current PS Ratio is 11.21, which is 11% below median its own 10-year median of 12.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.77, compared to a current price of ¥54.91 — trading 9.6% below its estimated fair value. The current PS Ratio is 11.21, which is 11% below median its 10-year median of 12.64 and 388.5% above the Drug Manufacturers industry median of 2.30. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current PS Ratio is 11.21 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥54.91 is trading 9.6% below its estimated GF Value™ of ¥60.77.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SHSE:600276:
PS Ratio: 11.21 (11% below median its 10-year median of 12.64)
GF Value™: ¥60.77 vs. price of ¥54.91 (9.6% below fair value)
Industry Position: 388.5% above the Drug Manufacturers median (#844 of 952)
No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
91GF Score
Get the complete analysis for SHSE:600276
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600276 has been successfully added to your 
